[13], [14] Use of synthetic PPAR agonists has been associated with lower likelihood and severity of pathologic retinal neovascularization. Troglitazone, a PPARG agonist, inhibited laser-induced choroidal neovascularization (a hallmark of NV AMD) in cynomoglus monkeys. [21] Fenofibrate, a PPAR activator, reduced the need for laser treatment for proliferative (neovascular) retinopathy in a large phase III clinical trial of 9795 people with type 2 diabetes. [22] The rationale for using PPAR ligands as therapeutic agents for NV AMD has been raised elsewhere. [23]. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.